González-Ponce F, Flores-Chávez A, Ramírez-Villafaña M, Pérez-Guerrero E, Romero-Moreno JR, Saucedo-Ulloa M, Aguirre-Romo A, Huerta-Viera M, Trujillo-Trujillo X, González-López LC

Idioma: Español
Referencias bibliográficas: 28
Paginas: 125-131
Archivo PDF: 258.87 Kb.

RESUMEN

La quemerina es una adipocina recientemente descrita cuyo papel es regular el metabolismo lipídico y glúcido a través de acciones sistémicas. El mecanismo preciso por el cual la quemerina puede estar asociada al síndrome metabólico no ha sido aún del todo comprendido. La unión de la quemerina con su respectivo receptor ocasionará posteriormente inhibición de la fosforilación del estimulador de la insulina y activación del 5-AMP proteína cinasa activada (AMPc), induciendo resistencia a la insulina en el músculo esquelético, considerado uno de los factores principales del desarrollo de SM. Las alteraciones en el perfil lipídico dentro del SM correlacionadas con los niveles séricos de quemerina parecen ser consecuencia de la resistencia a la insulina, en la cual se disminuye el transporte de glucosa al músculo esquelético, induciendo a gluconeogénesis hepática. Recientemente se ha sugerido que la quemerina juega un papel fundamental en el metabolismo y podría estar implicada en el desarrollo de SM, pues ésta se encuentra elevada en el tejido adiposo y se observan altos niveles circulantes de esta adipocina en pacientes con mayor grado de adiposidad en comparación con aquéllos de peso saludable.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148: 4687-4694.

2. Stejskal D, Karpiesek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population- a pilot Study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152 (2): 217-221.

3. Roh SG, Song SH, Choi KC, Katoh K, Wittamer V, Parmentier M et al. Chemerin-A new adipokine that modulates adipogenesis via its own receptor. Biochem Biophys Res Comm. 2007; 362: 1013-1018.

4. Chamberland JP, Berman RL, Aronis KN, Mantzoros CS. Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation and lacks day/night variation in humans. Eur J Endocrinol. 2013; 169 (4): 453-462. doi:10.1530/EJE-13-0098

5. Tan BK, Chen J, Farhatullah S, Adya R, Kaur J, Heutling D et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes. 2009; 58: 1971-1977.

6. Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology. 2010; 151: 2590-2602.

7. Meder W, Wendland M, Busmann A, Kutzleb C, Spodsberg N et al. Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23. FEBS Lett. 2003; 555: 495-499.

8. Zabel BA, Nakae S, Zúñiga L, Kim JY, Ohyama T, Pan J et al. Mast cell-expressed orphan receptor CCRL2 binds chemerin and is required for optimal induction of IgE-mediated passive cutaneous anaphylaxis. J Exp Med. 2008; 205: 2207-2220.

9. Bozaoglu K, Curran JE, Stocker CJ, Zaibi MS, Segal D et al. Chemerin, a novel adipokine in the regulation of angiogenesis. J Clin Endocrinol Metab. 2010; 95 (5): 2476-2485.

10. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282: 28175-28188.

11. Becker M, Rabe K, Lebherz C et al. Expression of human chemerin induces insulin resistance in skeletal muscle but does not affect weight, lipid levels, and atherosclerosis in LDL receptor knockout mice on high-fat diet. Diabetes. 2010; 59: 2898-2903.

12. Fatima SS, Bozaoglu K, Rehman R, Alam F, Memon AS. Elevated chemerin levels in Pakistani men: an interrelation with metabolic syndrome phenotypes. PLoS One. 2013; 8 (2): e57113.

13. Sesti G. Pathophysiology of insulin resistance. Best Pract Res Clin Endocrinol Metab. 2006; 20: 665-679.

14. Grundy SM, Cleeman JI, Merz CNB et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.

15. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. American Diabetes Association. Followup report on the diagnosis of diabetes mellitus. Diabetes Care. 2003; 26: 3160-3167.

16. González-Chávez A, Simental L, Elizondo-Argueta S et al. Prevalencia del síndrome metabólico entre adultos mexicanos no diabéticos, usando las definiciones de la OMS, NCEP-ATPIIIa e IDF. Rev Med Hosp Gen Mex. 2008; 71 (1): 11-19.

17. Rojas R, Aguilar-Salinas CA, Jiménez-Corona A et al. Metabolic Syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006. Salud Pública de México. 2010; 52 (1): S11-S18.

18. Pineda CA. Síndrome metabólico: definición, historia, criterios. Colombia Médica. 2008; 39 (1): 96-106.

19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15: 539-553.

20. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999; 16: 442-443.

21. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.

22. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9: 237-252.

23. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. Disponible en: http://www.idf.orgwebdata/docs/IDF_Metasyndrome_definition.pdf

24. Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B et al. AHA/NHLBI Scientific statement. Diagnosis and management of the metabolic syndrome. Circulation. 2005; 112: 2735-2752.

25. Wang D, Yuan GY, Wang XZ et al. Plasma chemerin level in metabolic syndrome. Genetics and Molecular Research. 2013; 12 (4): 5986-5991.

26. Chu SH, Lee MK, Ahn KY et al. Chemerin and adiponectin contribute reciprocally to metabolic syndrome. PLoS ONE. 2012; 7 (4): e34710.

27. Bozaoglu K, Segal D, Shields KA, Cummings N et al. Chemerin is associated with metabolic Syndrome phenotypes in a Mexican-American Population. J Clin Endocrino Metab. 2009; 94 (8): 3085-3088.

28. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3–L1 adipocytes. FEBS Lett. 2008; 582: 573-578.